<![CDATA[Genmab: Video - Subcutaneous epcoritamab]]>Martin Hutchings, MD, PhD, of Copenhagen University Hospital, Copenhagen, Denmark, discusses the results from a Phase I/II dose-escalation study investigating subcutaneous epcoritamab (CD3xCD20) in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma. Additionally, Dr Hutchings outlines safety signals detected during the clinical trial. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

]]>https://dev.proinvestor.com/forum/topic/441462/genmab-video-subcutaneous-epcoritamabRSS for NodeFri, 10 Jul 2026 12:36:44 GMTFri, 19 Jun 2020 13:19:22 GMT60